Amoy Diagnostics Co Ltd
SZSE:300685
Intrinsic Value
Amoy Diagnostics Co., Ltd. engages in the research, development, production and sale of tumour precision medical molecular diagnostic products. [ Read More ]
The intrinsic value of one
Amoy Diagnostics Co Ltd
stock under the Base Case scenario is
20.77
CNY.
Compared to the current market price of 21.78 CNY,
Amoy Diagnostics Co Ltd
is
Overvalued by 5%.
Amoy Diagnostics Co Ltd's market capitalization is 8.6B CNY.
Amoy Diagnostics Co Ltd stock price is 21.78 CNY.
Amoy Diagnostics Co Ltd stock (20.77 CNY) is 5% less than its price (21.78 CNY).
Amoy Diagnostics Co Ltd stock (10.05 CNY) is 54% less than its price (21.78 CNY). Open DCF Valuation
Amoy Diagnostics Co Ltd stock price (21.78 CNY) is 31% less than its Relative Value (31.49 CNY). Open Relative Valuation
Amoy Diagnostics Co Ltd has upside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
Amoy Diagnostics Co Ltd's Revenue has grown by 9% over the past 12 months.
Amoy Diagnostics Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Amoy Diagnostics Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 19% to 14%.
Amoy Diagnostics Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 20%.
Amoy Diagnostics Co Ltd's Revenue has been growing by 14% per year for the last 3 years.
Amoy Diagnostics Co Ltd has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
Amoy Diagnostics Co Ltd has positive Operating Income for the last twelve months.
Amoy Diagnostics Co Ltd's Revenue is forecast to grow at a rate of 23% per year over the next 3 years.
Amoy Diagnostics Co Ltd has positive Net Income for the last twelve months.
Amoy Diagnostics Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 37% to 20%.
Amoy Diagnostics Co Ltd has positive Free Cash Flow for the last twelve months.
Amoy Diagnostics Co Ltd has very high three-year average ROIC (Return on Invested Capital): 28%. The company is very efficient at using invested capital to generate operating income.
Amoy Diagnostics Co Ltd has positive Gross Profit for the last twelve months.
Amoy Diagnostics Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.03.
Amoy Diagnostics Co Ltd's short-term assets (1B CNY) exceed its short-term liabilties (93m CNY).
Amoy Diagnostics Co Ltd's long-term assets (2B CNY) exceed its long-term liabilties (152m CNY).
Amoy Diagnostics Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (502m CNY) than debt (47m CNY).
Amoy Diagnostics Co Ltd's Altman Z-Score is very high and is equal to 41.07.
Valuation Backtest
Amoy Diagnostics Co Ltd
Run backtest to discover the historical profit from buying and selling
Amoy Diagnostics Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Amoy Diagnostics Co Ltd
Balance Sheet Decomposition
Amoy Diagnostics Co Ltd
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 502.3m |
| Receivables | 492.6m |
| Other Current Assets | 358.7m |
| Non-Current Assets | 357.9m |
| Long-Term Investments | 52.6m |
| PP&E | 203.5m |
| Intangibles | 46.3m |
| Other Non-Current Assets | 55.6m |
| Current Liabilities | 92.7m |
| Accounts Payable | 13.7m |
| Accrued Liabilities | 54.7m |
| Short-Term Debt | 461.9k |
| Other Current Liabilities | 23.8m |
| Non-Current Liabilities | 59m |
| Long-Term Debt | 46.6m |
| Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
Amoy Diagnostics Co Ltd
|
Revenue
|
950.5m
CNY
|
|
Cost of Revenue
|
-167.6m
CNY
|
|
Gross Profit
|
782.9m
CNY
|
|
Operating Expenses
|
-570.3m
CNY
|
|
Operating Income
|
212.5m
CNY
|
|
Other Expenses
|
787.5k
CNY
|
|
Net Income
|
213.3m
CNY
|
Free Cash Flow Analysis
Amoy Diagnostics Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Amoy Diagnostics Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Amoy Diagnostics Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Amoy Diagnostics Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Amoy Diagnostics Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Amoy Diagnostics Co Ltd
According to Wall Street analysts, the average 1-year price target for
Amoy Diagnostics Co Ltd
is 30.42 CNY
with a low forecast of 26.26 CNY and a high forecast of 40.95 CNY.
Shareholder Return
Price
Amoy Diagnostics Co Ltd
| Average Annual Return | 17.11% |
| Standard Deviation of Annual Returns | 44.01% |
| Max Drawdown | -88% |
| Market Capitalization | 8.6B CNY |
| Shares Outstanding | 398 601 984 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Amoy Diagnostics Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Amoy Diagnostics Co., Ltd. engages in the research, development, production and sale of tumour precision medical molecular diagnostic products. The company is headquartered in Xiamen, Fujian and currently employs 1,096 full-time employees. The company went IPO on 2017-08-02. The firm provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The firm also provides data software to capture and analyze gene sequencing data. The firm provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
Contact
IPO
Employees
Officers
The intrinsic value of one
Amoy Diagnostics Co Ltd
stock under the Base Case scenario is
20.77
CNY.
Compared to the current market price of 21.78 CNY,
Amoy Diagnostics Co Ltd
is
Overvalued by 5%.
You don't have any saved screeners yet
